Prime Medicine, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PRME Nasdaq 2836 primemedicine.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Prime Medicine, Inc.

Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity - Sep 29th, 2026 7:00 am
Prime Medicine stock surges on FDA IND clearance - Sep 24th, 2026 2:47 pm
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency - Sep 24th, 2026 2:01 pm
Anthropic AI Discovery Gene-Editing Stocks Falling - Sep 24th, 2026 6:46 am
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks? - Sep 23rd, 2026 3:49 pm
In Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036) - Sep 18th, 2026 9:38 am
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout - Sep 17th, 2026 2:09 pm
Prime Medicine to Participate in Upcoming Investor Conferences - Sep 3rd, 2026 6:00 am
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates - Aug 6th, 2026 7:50 am
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates - Aug 6th, 2026 6:00 am
Scribe’s Genetic Editing Aims to Prevent Heart Attacks - Jul 30th, 2026 8:26 am
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - Jul 30th, 2026 8:00 am
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease - Jul 23rd, 2026 2:05 pm
Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM) - Jul 15th, 2026 8:01 am
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics - Jul 15th, 2026 2:53 am
Cathie Wood Dumps AMD, Doubles Down on Meta Stock - Jul 10th, 2026 6:57 am
Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically? - Jul 9th, 2026 2:14 pm
Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle - Jul 8th, 2026 2:09 pm
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Jul 8th, 2026 10:47 am